TrumpRx.gov Launch Targets Lower Prescription Drug Prices in United States

Key Takeaways

• A new federal website, TrumpRx.gov, provides access to discounted pricing on 40 high-cost branded prescription drugs using most-favored-nation (MFN) benchmarks.
• Initial participating manufacturers include AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, with additional products expected.
• Discounts apply to medications commonly used in diabetes, obesity, fertility treatment, respiratory disease, dermatology, and menopause care.

A new federal initiative aims to reduce prescription drug costs for US patients through the launch of TrumpRx.gov, a publicly accessible website offering discounts tied to MFN pricing. The platform allows eligible patients with valid prescriptions to access lower prices on select high-cost branded medications, with pricing aligned to levels paid in other developed nations.

Program Overview and Drug Pricing Details

TrumpRx.gov launched with discounted pricing on 40 branded medications that represent some of the highest prescription drug expenditures in the US. The program initially includes products from 5 manufacturers—AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer—that have entered MFN pricing agreements with the federal government. Additional drugs from other manufacturers are expected to be added in the coming months.

Depending on the manufacturer, patients may access savings through printable or mobile coupons or through manufacturer-supported distribution channels integrated into the website. Pricing mechanisms and redemption processes vary by product.

Among the most notable reductions are therapies used for diabetes, obesity, and cardiovascular risk reduction. Monthly prices for Ozempic and injectable Wegovy were reduced from $1028 and $1349 to an average of $350, with some dosages priced as low as $199. Oral Wegovy pricing was reduced to as low as $149 per month. Zepbound pricing decreased from $1088 to an average of $346.

Substantial reductions were also announced for fertility medications, which are frequently paid for out-of-pocket. Gonal-F pricing was reduced to as low as $168 per pen, while Cetrotide decreased from $316 to $22.50 and Ovidrel from $251 to $84.

Additional discounted therapies include Bevespi Aerosphere for chronic obstructive pulmonary disease ($458 to $51), Airsupra for asthma ($504 to $201), Eucrisa for atopic dermatitis ($792 to $158), Insulin Lispro (as low as $25 per month), and Duavee for menopausal symptoms and osteoporosis prevention ($202 to $30).

Considerations for Prescribing and Access

The availability of MFN-based pricing through TrumpRx.gov may affect patient access to high-cost branded medications, particularly for conditions associated with long-term treatment and significant out-of-pocket expenses. Therapies for diabetes, obesity, infertility, and respiratory disease are commonly associated with cost-related nonadherence.

Lower pricing may improve treatment initiation and persistence, especially among uninsured or underinsured patients. Clinicians may need to discuss manufacturer-specific access pathways with patients, as discount mechanisms differ by product and may not integrate directly with insurance coverage.

The initiative may also influence prescribing discussions when multiple therapeutic options are clinically appropriate but differ substantially in cost. However, interactions with commercial insurance plans, pharmacy benefit managers, and public payers were not detailed and may affect real-world utilization.

Conclusion

The launch of TrumpRx.gov introduces a new mechanism for applying MFN pricing to select prescription drugs in the United States. As additional medications and manufacturers are added, clinicians and health systems will need to assess how the program influences affordability, adherence, and patient access to therapy.

Reference

Fact sheet: President Donald J. Trump launches TrumpRx.gov to bring lower drug prices to American patients. The White House. Published February 5, 2026. Accessed February 6, 2026. https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/